Abbott Laboratories Finalizes Major Acquisition in Cancer Diagnostics

Abbott Laboratories completes its $23 billion acquisition of Exact Sciences, gaining key cancer tests like Cologuard and Oncotype DX to enter the $60B oncology market.

Abbott Laboratories is set to complete its acquisition of Exact Sciences on Monday, March 23, 2026. Valued at approximately $23 billion, this transaction ranks among the largest in Abbott's corporate history and represents a significant strategic move into the expanding cancer diagnostics sector.

Strategic Rationale and Market Position

The acquisition grants Abbott immediate access to established cancer screening platforms, including the Cologuard colorectal cancer test system, the Oncotype DX breast cancer assay, and newer diagnostic tools such as Oncodetect and Cancerguard. Exact Sciences, headquartered in Madison, will operate as a wholly-owned subsidiary following the deal's closure. This move positions Abbott directly within the U.S. cancer prevention and precision oncology market, which is estimated to be worth around $60 billion.

Financial Impact and Integration Challenges

For the ongoing 2026 fiscal year, Abbott anticipates the newly integrated business to contribute roughly $3 billion in revenue. This is expected to accelerate the company's organic sales growth by approximately 0.5 percentage points. However, management concurrently forecasts a dilution of adjusted earnings per share of about $0.20. This adjustment is typical for a deal of this scale, reflecting the costs associated with integration and financing.

Abbott shares currently trade about 15% below their 200-day moving average and have seen a notable decline since the start of the year. Whether this acquisition becomes a medium-term catalyst for the stock price will largely depend on the smoothness of the integration process. Abbott must successfully embed Exact Sciences's complex oncology platforms into its existing global diagnostics infrastructure—a task that historically consumes several quarters.

The success of this substantial investment hinges on Abbott's execution in merging these advanced diagnostic capabilities, with the market watching closely for updates on operational synergy and growth delivery.